北京商报讯（记者 丁宁）10月16日晚间，康华生物（300841）发布2025年第三季度报告显示，公司前 三季度实现营业收入8.4亿元，同比下降20.78%；归属净利润1.89亿元，同比下降53.41%。 康华生物表示，剔除上年重组六价诺如疫苗海外授权收入后，年初至报告期末营业收入较上年同期下降 11.96%，其中非免疫规划疫苗销售收入年初至报告期末较上年同期下降11.97%， 年初至报告期末净利 润较上年同期下降40.08%。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）10月16日，康华生物发布公告称，2025年第三季度实现营 业收入3.56亿元，同比增长11.54%；归属于上市公司股东的净利润为7459.01万元，同比下降24.92%； 归属于上市公司股东的扣除非经常性损益的净利润为7176.47万元，同比下降30.82%。2025年前三季度 实现营业收入8.4亿元，同比下降20.78%；归属于上市公司股东的净利润为1.89亿元，同比下降 53.41%；归属于上市公司股东的扣除非经常性损益的净利润为1.83亿元，同比下降55.57%。 ...

智通财经APP讯，康华生物(300841.SZ)发布2025年三季度报告，该公司前三季度营业收入为8.4亿元， 同比减少20.78%。归属于上市公司股东的净利润为1.89亿元，同比减少53.41%。归属于上市公司股东的 扣除非经常性损益的净利润为1.83亿元，同比减少55.57%。基本每股收益为1.4553元。 ...

Core Viewpoint - Kanghua Biotech reported a significant decline in both revenue and net profit for the first three quarters of the year, indicating potential challenges in its business performance [1] Financial Performance - The company's operating revenue for the first three quarters was 840 million yuan, representing a year-on-year decrease of 20.78% [1] - The net profit attributable to shareholders was 189 million yuan, down 53.41% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 183 million yuan, reflecting a year-on-year decline of 55.57% [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Kanghua Biological in Q3 2025, showing a significant decline in revenue and net profit compared to the previous year [1] - The company's revenue for the first three quarters of 2025 is approximately 840 million yuan, representing a year-on-year decrease of 20.78% [1] - The net profit attributable to shareholders is about 189 million yuan, reflecting a year-on-year decrease of 53.41% [1] - The basic earnings per share stand at 1.4553 yuan, which is a decrease of 52.59% year-on-year [1] Group 2 - As of the report date, Kanghua Biological has a market capitalization of 10.2 billion yuan [2]

Core Insights - The company reported third-quarter revenue of 356 million yuan, representing a year-on-year increase of 11.54% [1] - Net profit for the third quarter was 74.59 million yuan, showing a year-on-year decline of 24.92% [1] - For the first three quarters, total revenue was 840 million yuan, reflecting a year-on-year decrease of 20.78% [1] - Net profit for the first three quarters amounted to 189 million yuan, down 53.41% year-on-year [1]

第三届监事会第八次会议决议公告 （一） 审议通过《关于2025年第三季度报告的议案》 公司编制和审议2025年第三季度报告的程序符合法律、行政法规、中国证监 会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了公司的实 际情况，不存在虚假记载、误导性陈述或者重大遗漏。 本公司及监事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届监事会第八次会 议通知已于2025年10月13日以专人送达、邮件等方式向全体监事发出。会议于 2025年10月15日以线上会议的方式召开。本次会议应出席监事3名，实际出席监 事3名。会议由监事会主席吴淑青女士召集并主持。本次会议的召集、召开程序 符合《中华人民共和国公司法》等法律、法规、规范性文件和《成都康华生物制 品股份有限公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 经与会监事认真讨论，审议并通过如下议案： 证券代码：300841 证券简称：康华生物 公告编号：2025-052 成都康华生物制品股份有限公司 具体内容详见公司同日在巨潮资讯网 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-054 成都康华生物制品股份有限公司 第三届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025 年第三季度报告》（公告编号：2025-053）。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 三、 备查文件 1、公司第三届董事会第八次会议决议； 2、公司第三届董事会审计委员会第五次会议决议； 3、深交所要求的其他文件。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第八次会 议通知于2025年10月13日以专人送达、邮件等方式向全体董事和监事发出，会议 于2025年10月15日在公司会议室以现场与线上结合的方式召开；本次会议由董事 长王振滔先生召集并主持，会议应出席董事8人，实际出席董事8人，公司监事、 高级管理人员列席了本次会议。本次会议的召集和召开程序符合《中华人民共和 国公司法》《成都康华生物制品股份有限公司章程》等有关规定，会议 ...

[Important Notice](index=2&type=section&id=Important%20Notice) This section outlines the company's declarations regarding the report's accuracy and completeness, confirming the financial information is unaudited [Report Statement and Audit Status](index=2&type=section&id=Report%20Statement%20and%20Audit%20Status) The board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness; financial information is declared true, complete, and unaudited - The board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness, and assume legal responsibility[4](index=4&type=chunk) - The company's head, chief accountant, and head of accounting department declare the financial information to be true, accurate, and complete[4](index=4&type=chunk) - The third-quarter financial report is **unaudited**[5](index=5&type=chunk) [I. Key Financial Data](index=3&type=section&id=I.%20Key%20Financial%20Data) This section presents the company's key accounting data and financial indicators, highlighting significant changes in profitability, assets, liabilities, and cash flows [1. Key Accounting Data and Financial Indicators](index=3&type=section&id=1.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Operating revenue increased year-on-year, but net profit attributable to shareholders and non-recurring net profit significantly decreased, with larger declines in profitability and net operating cash flow from year-to-date Key Financial Indicators for the Current Period and Year-to-Date | Indicator | Current Period (CNY) | YoY Change (%) | Year-to-Date (CNY) | YoY Change Year-to-Date (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 356,143,615.07 | 11.54% | 840,062,581.82 | -20.78% | | Net Profit Attributable to Shareholders of Listed Company | 74,590,140.27 | -24.92% | 189,110,720.76 | -53.41% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-Recurring Gains and Losses | 71,764,743.04 | -30.82% | 183,318,264.19 | -55.57% | | Net Cash Flow from Operating Activities | -- | -- | 153,725,204.88 | -39.22% | | Basic Earnings Per Share (CNY/share) | 0.5740 | -24.49% | 1.4553 | -52.59% | | Diluted Earnings Per Share (CNY/share) | 0.5740 | -24.49% | 1.4553 | -52.59% | | Weighted Average Return on Net Assets | 2.15% | -0.74% | 5.43% | -6.11% | Balance Sheet Indicators at Period End vs. Prior Year End | Indicator | Current Period End (CNY) | Prior Year End (CNY) | Change from Prior Year End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 3,937,496,245.21 | 4,027,582,273.97 | -2.24% | | Owners' Equity Attributable to Shareholders of Listed Company | 3,506,672,518.04 | 3,447,508,696.28 | 1.72% | - Excluding prior year's reclassified hexavalent norovirus vaccine overseas licensing revenue, year-to-date operating revenue decreased by **11.96%**, net profit by **40.08%**, and non-recurring net profit by **43.12%**[6](index=6&type=chunk) [2. Non-Recurring Gains and Losses Items and Amounts](index=3&type=section&id=2.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the current period were **CNY 2.83 million** and **CNY 5.79 million** year-to-date, mainly from government grants, fair value changes of financial assets, and investment income from associates Non-Recurring Gains and Losses Items and Amounts | Item | Current Period Amount (CNY) | Year-to-Date Amount (CNY) | Description | | :--- | :--- | :--- | :--- | | Gains or losses from disposal of non-current assets | 0.00 | -8,912.45 | | | Government grants recognized in current profit or loss | 258,911.37 | 1,795,232.74 | | | Gains or losses from changes in fair value of financial assets and liabilities, and investment income from disposal of financial assets and liabilities | 2,900,708.16 | 4,908,108.17 | Fair value changes of associates, wealth management income, and investment income from associates | | Other non-operating income and expenses apart from the above | -6,252.67 | -46,493.28 | | | Less: Income tax impact | 327,969.63 | 855,478.61 | | | Total | 2,825,397.23 | 5,792,456.57 | -- | [3. Analysis of Changes in Key Accounting Data and Financial Indicators](index=4&type=section&id=3.%20Analysis%20of%20Changes%20in%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Significant changes occurred across balance sheet, income statement, and cash flow statement items, with notable shifts in receivables, deferred tax assets, construction in progress, investment income, impairment losses, and cash flows from operations and financing Key Changes in Consolidated Balance Sheet Items and Reasons (Period End vs. Year Start) | Balance Sheet Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Other Receivables | 78.21% | Due to accrual of employee compensation | | Other Current Assets | 60.90% | Due to increase in estimated return receivables | | Construction in Progress | -100.00% | Due to completion and capitalization of construction in progress | | Deferred Income Tax Assets | 100.08% | Due to accrual of credit impairment losses and inventory depreciation reserves | | Notes Payable | -100.00% | Due to payment of matured notes | | Accounts Payable | -60.19% | Due to payment of procurement settlements | | Contract Liabilities | -56.07% | Due to decrease in advances from customers | | Employee Compensation Payable | -31.52% | Due to payment of employee compensation for 2024 | | Taxes Payable | 99.57% | Due to income tax adjustments | | Other Payables | -34.40% | Due to settlement of promotion fees and engineering equipment payments | | Other Current Liabilities | -56.07% | Due to decrease in contract liabilities | | Deferred Income | 35.75% | Due to receipt of asset-related government grants | | Treasury Stock | -100.00% | Due to cancellation of treasury stock | Key Changes in Consolidated Income Statement Items and Reasons (Year-to-Date vs. Prior Year Period) | Income Statement Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Financial Expenses | 51.36% | Due to decrease in interest income | | Investment Income (Losses indicated by "-") | 214.41% | Due to investment income from associates | | Gains from Changes in Fair Value (Losses indicated by "-") | 123.70% | Due to fair value changes of associates | | Credit Impairment Losses (Losses indicated by "-") | 63.03% | Due to decrease in bad debt provisions for accounts receivable and other receivables | | Asset Impairment Losses (Losses indicated by "-") | -438.17% | Due to impairment provisions made as per regulations | | Gains from Asset Disposal (Losses indicated by "-") | 99.50% | Due to decrease in asset disposals | | Non-Operating Expenses | -78.29% | Due to decrease in donation expenses | | Income Tax Expense | -42.44% | Due to decrease in operating profit | Key Changes in Consolidated Cash Flow Statement Items and Reasons (Year-to-Date vs. Prior Year Period) | Cash Flow Statement Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -39.22% | Due to reduced product sales collections and overseas licensing revenue collections | | Net Cash Flow from Investing Activities | 7.27% | Due to reduced investment in fixed assets | | Net Cash Flow from Financing Activities | 60.48% | Due to reduced share repurchases and dividend distributions | [II. Shareholder Information](index=5&type=section&id=II.%20Shareholder%20Information) This section details the company's common and preferred shareholder structure, including top shareholders, their holdings, and changes in restricted shares [1. Common Shareholder Holdings and Top Ten Shareholders](index=5&type=section&id=1.%20Common%20Shareholder%20Holdings%20and%20Top%20Ten%20Shareholders) As of the reporting period end, the company had **18,290 common shareholders**, with Aokang Group and Wang Zhentao as parties acting in concert among the top ten, holding significant pledged stakes - As of the end of the reporting period, the total number of common shareholders was **18,290**, with no preferred shareholders whose voting rights have been restored[14](index=14&type=chunk) Top 10 Shareholder Holdings | Shareholder Name | Shareholder Nature | Holding Ratio (%) | Number of Shares Held (shares) | Number of Restricted Shares Held (shares) | Pledge, Mark or Freeze Status (Status/Number of Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Aokang Group Co., Ltd. | Domestic Non-State-Owned Legal Person | 12.55% | 16,305,468 | 0 | Pledged/11,725,000 | |

关于收到《经营者集中反垄断审查不予禁止决定书》 暨公司控制权拟发生变更的进展公告 证券代码：300841 证券简称：康华生物 公告编号：2025-051 成都康华生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、其他说明及风险提示 一、基本情况概述 成都康华生物制品股份有限公司（以下简称"公司"）控股股东、实际控制人 王振滔先生及其一致行动人奥康集团有限公司（以下简称"奥康集团"）、持股 5%以上股东济南康悦齐明投资合伙企业（有限合伙）（以下简称"康悦齐明"） 与上海万可欣生物科技合伙企业（有限合伙）（以下简称"万可欣生物"）于 2025 年 7 月 18 日签订了《股份转让协议》，同日王振滔与万可欣生物签订了《表决 权委托协议》。根据《股份转让协议》，王振滔、奥康集团、康悦齐明拟合计向 万可欣生物转让所持有的公司 2,846.6638 万股股份，占《股份转让协议》签订之 日剔除公司回购账户股份后总股本的 21.9064%。根据《表决权委托协议》，王 振滔在本次股份转让后，将转让后持有的公司 1,050.3517 万股股份（占《表决权 ...